Gillespie Named Interim Associate Senior VP of Development and Alumni Affairs
The office of development and alumni affairs raises more than $20 million annually for the UC colleges of medicine, nursing, pharmacy and allied health sciences. It also serves the more than 20,000 graduates of the four health professions colleges.
We look forward to working closely with John as we work to engage our alumni and friends throughout the community in support of
Gillespie has been associated with the university for the past 30 years. Since 1998 he has served as director of marketing and development for UC Physicians, the 500-member faculty group practice. He also serves as executive director and treasurer of the Medical Center Fund of Cincinnati, which invests the reserves for the UC Physicians practices.
Prior to those appointments he served in a variety of administrative leadership roles with clinical departments at the
A native of
Gillespie will continue to serve with UC Physicians and the Medical Center Fund of Cincinnati during this interim period.
Related Stories
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.
Phase 1 trial tests probiotic treatment for radiation side effects in the gut
March 9, 2026
The University of Cincinnati Cancer Center’s Bailey Nelson, MD, has been awarded a $50,000 pilot grant from the Cancer Center to open a Phase 1 trial testing if a probiotic supplement can reduce gastrointestinal symptoms for patients undergoing whole pelvis radiotherapy.
Is uACR the key to cardiovascular and kidney disease prevention?
March 8, 2026
As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.